Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Feb 06, 2019 - GlaxoSmithKline (NYSE:GSK) Q4 2018 Results Conference Call February 06, 2019 09:00 AM ET Company Participants Sarah Elton-Farr - Head of Investor Relations Emma Walmsley - Chief Executive Officer Simo
Feb 06, 2019 - GSK earnings call for the period ending December 31, 2018.
Feb 06, 2019 - Earnings Data Deluge
Feb 06, 2019 - Plenty of Q4 earnings numbers join new Manufacturing and Trade data, some of which had been previously delayed due to the government shutdown.
Feb 05, 2019 - A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.
Feb 04, 2019 - Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.
Feb 01, 2019 - Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.
Feb 01, 2019 - GlaxoSmithKline (GSK) closed at $39.20 in the latest trading session, marking no change from the prior day.